A 75-year-old woman developed depression in 2010 and was treated with oral medications at our Department of Psychiatry. Since she showed no tendency toward improvement, she underwent modified electroconvulsive therapy (mECT). Later, she developed severe liver injury that was presumably induced by the propofol used for mECT. Propofol is an intravenous anesthetic agent that reportedly can be used relatively safely in the presence of liver dysfunction. We herein report the first case of propofol-induced liver injury definitively diagnosed based on positive drug lympocyte stimulation testing (DLST).
Introduction
Propofol is an intravenous anesthetic agent that was approved for coverage under the national health insurance system in 1995. It is believed to activate the GABAA receptor, inhibit the N-methyl-D-aspartic acid receptor and modulate calcium influx through calcium ion channels, thereby generating an inhibitory postsynaptic potential and inducing unconsciousness (1) . Propofol is primarily metabolized in the liver by glucuronic acid and sulfate conjugation and excreted through the kidneys as an inactive metabolite (2) . Therefore, it is metabolized to products without anesthetic properties and is considered not to accumulate. To date, there are no reports of propofol-induced liver injury definitively diagnosed based on drug lymphocyte stimulation testing (DLST). In addition, no cases of propofol-induced liver injury have been reported in Japan. We herein report a case of liver injury that was found to have been caused by propofol used during modified electroconvulsive therapy (mECT) for depression and review the literature.
Case Report
The patient was a 75-year-old Japanese woman (149 cm tall and weighing 36.7 kg) with a drug history of a quetiapine fumarate allergy that manifested as liver damage. After depression was diagnosed in July 2010, she was followed up at an outpatient clinic, then admitted to the Department of Psychiatry at our hospital in October of the same year due to worsening anorexia and difficulty communicating. Because oral antidepressant treatment did not result in symptomatic improvement, the patient underwent three episodes of mECT under intravenous propofol anesthesia. As laboratory tests performed on the 18th day of treatment (five days after the last treatment) showed severe liver dysfunction, she was referred to our department. When first examined, her level of consciousness was normal. Her blood pressure was 111/78 mmHg and her pulse was 100 beats/ min and regular. She had no anemia or jaundice. Her abdomen was unremarkable. Initial laboratory tests performed in our department revealed hepatocellular injury: the serum aspartate aminotransferase (AST) level was 4,683 IU/mL, the alanine aminotransferase (ALT) level was 3,246 IU/mL, the alkaline phosphatase (ALP) level was 632 IU/mL and the γ- GTP level was 166 IU/mL. The patient's hepatic function was evaluated based on the following test results: a prothrombin activity level of 89%, a platelet count of 234,000/mL and an albumin level of 3.3 g/dL. She had no evidence of Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis E Virus (HEV) or other viral infection as a cause of the liver dysfunction and no autoimmune diseases, history of alcohol abuse or any abnormalities in lipid, copper or iron metabolism (Table 1). Abdominal ultrasound did not show any findings suggestive of chronic liver injury. DLST for propofol was positive 18 days after the first mECT treatment. Consequently, the patient scored 10 on the DDW-J 2004 diagnostic scale for drug-induced liver injury and received a definitive diagnosis of propofol-induced hepatocellular liver injury. In addition, leukopenia was noted, leading to a diagnosis of drug-induced leukopenia. The drugs were therefore discontinued, and glycyrrhizin was administered at a dose of 60 ml/day starting 18 days after mECT treatment. Subsequently, the patient's liver dysfunction improved, and an ultrasound-guided liver biopsy was performed 26 days after the initiation of treatment (eight days after the liver injury). A histological examination showed mild lymphocytic infiltration of the portal tracts, no cholangiolar hyperplasia and almost no fibrosis (Fig. 1 ). There were no changes to suggest acute viral hepatitis or chronic liver disease. These findings were consistent with a diagnosis of drug-induced liver injury.
On the 60th day after the initiation of treatment, the patient's liver function returned to normal and mECT was again performed for depression under anesthesia administered with agents other than propofol (Fig. 2) . Thereafter, no liver dysfunction was observed and mECT was noted to have a therapeutic effect. Moreover, the leukopenia gradually improved after the drug discontinuation, and the patient was discharged on the 120th hospital day.
Discussion
With advances in medical science, new drugs have been introduced into clinical practice. Many of these drugs and agents, previously considered safe, have been reported to induce liver injury (2, 3). All drugs may potentially induce liver injury, with different frequencies and severity. In Japan, drugs are believed to induce acute hepatitis in 10% and jaundice in 5% of cases, respectively. Drug-induced liver injury is classified into the following categories: 1. direct drug toxicity in which the drugs and their metabolites physicochemically and in a dose-dependent manner induce liver injury either directly or through metabolic disturbances, the toxic effects of which have been demonstrated in animal experiments and show similar features in all patients; 2. drug hypersensitivity induced by drugs and their metabolites in a dose-independent manner via an allergic mechanism in a small number of patients-a mechanism that cannot be reproduced in experimental animals and in which the patients are DLST-positive. Liver injury is also classified morphologically into hepatocellular, cholestatic and mixed types. The scoring system recommended by the DDW-J 2004 Drug-Induced Liver Injury Workshop is commonly used as a diagnostic criterion for drug-induced liver injury, with a reported sensitivity of 98.7% and a specificity of 97% (4). The present patient was DLST-positive and scored 10 on the diagnostic criteria for drug-induced liver injury of the DDW-J 2004 Workshop. Hepatocellular drug-induced liver injury due to hypersensitivity was thus diagnosed.
Propofol induces hypnosis by activating the GABAA receptor and thereby generating an inhibitory postsynaptic potential. It is primarily metabolized in the liver. Drug metabolism in the liver is divided into two phases. Phase I involves nonsynthetic reactions such as oxidation, reduction and hydrolysis, primarily catalyzed by cytochrome P450 (CYP), while phase II involves synthetic reactions (conjugations) such as glucuronidation and methylation. Phase 1, character-
Table 2. Cases of Acute Hepatitis after Sedation with Propofol in Literatures
ized by a low metabolic rate that is easily influenced by liver injury, is the rate-limiting step in drug metabolism. In contrast, phase II, which is characterized by a high metabolic rate that is little influenced by liver injury, is believed to be controlled by the liver blood flow. The rate of uptake of propofol by the liver is very high (nearly 100%), and because it contains a phenolic hydroxyl group propofol undergoes direct glucuronic acid or sulfate conjugation in phase II reactions without undergoing phase I reactions (1). The halflife of the drug in blood is 2-8 minutes, and the primary metabolites formed are phase II metabolites.
The metabolites of propofol have no anesthetic effects and are mostly excreted by the kidneys, with 70% being excreted within 24 hours (5). Furthermore, propofol administered during the anhepatic phase of liver transplantation has been reported to undergo glucuronic acid conjugation, indicating extrahepatic metabolism (6) . It has been reported that there are no differences in the pharmacokinetics of propofol after administration to patients with cirrhosis or to those with a normal liver function (7) . In addition, the use of propofol sedation for upper endoscopy is efficacious and well tolerated in patients with liver disease (8) . Therefore, propofol use is considered to be relatively safe, even in patients with liver injury. However, the present patient was found to be DLST-positive with severe hepatocellular injury and was therefore diagnosed with propofol-induced hepatocellular injury due to hypersensitivity, which has not been previously reported in Japan. Kansaku et al. reported that the CYP2B6 and UGT1A9 genotypes play major roles in propofol oxidation. The G/T genotype of CYP2B6-G516T, which was detected in this patient, is a genetic marker of an impaired CYP2B6 function (9) .
A review of the world literature revealed just four cases of liver injury apparently induced by propofol reported in references (10) (11) (12) (13) . In two of these cases, liver biopsies were performed to evaluate the histological findings, which were found to be consistent with liver injury induced by drug toxicity. However, in none of these cases was DLST performed to determine the cause (Table 2) ; therefore, it is not clear whether propofol was the cause of the liver injury. Hence, our case appears to be the first case worldwide in which propofol was definitively identified as the cause of liver injury.
As used in this case to treat depression, mECT is a procedure associated with a very low risk, and mortality statistics show that two deaths occur per 100,000 mECT sessions, indicating a risk similar to that encountered with anesthesia. It is thought that the risk of mECT is primarily due to compromise of the cerebral and cardiovascular function associated with post-mECT tachycardia (14) . The stimuli produced by mECT are thought not to reach the liver due to the high resistance of intervening body tissues, and many studies have reported that mECT can be safely performed, even in patients with implanted cardiac pacemakers (14-17), supporting the concept that mECT stimuli are unlikely to affect the liver. Studies have also reported that no significant increases in the AST levels are observed in blood samples collected at intervals up to 96 hours after mECT (18, 19) , suggesting a low possibility that liver dysfunction was caused by mECT itself in the present case.
We herein described the first reported case of propofolinduced liver injury, as demonstrated by DLST. Since all medications may cause hepatic injury, it is necessary to keep the possibility of drug-induced liver injury in mind when treating patients.
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